<DOC>
	<DOCNO>NCT01635907</DOCNO>
	<brief_summary>This study conduct evaluate whether investigational drug Dovitinib , shrink slow growth cancer patient certain type neuroendocrine tumor . This study also evaluate safety drug .</brief_summary>
	<brief_title>Dovitinib Neuroendocrine Tumors</brief_title>
	<detailed_description>This investigator-initiated study conduct evaluate whether investigational drug , Dovitinib , shrink slow growth cancer patient certain type neuroendocrine tumor ( advanced malignant pheochromocytoma paraganglioma ) . The primary endpoint response rate ( Complete + Partial Response ) determine RECIST v 1.1 . 25 subject enrol study University Pennsylvania .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<criteria>Patients advance , metastatic , recurrent unresectable paraganglioma pheochromocytoma . Pathology report pathology slide ( H &amp; E ) confirm histological diagnosis must available time enrollment . Must measurable disease RECIST v1.1 . ECOG performance status 0 , 1 , 2 Age great equal 18 year old Adequate laboratory result ; negative pregnancy test ( female childbearing potential ) Patients give write informed consent obtain accord institutional guideline Patients know untreated brain metastasis exclude . Patients history brain metastasis previously irradiate resect great 3 month prior enrollment clinically radiographically stable consider enrollment . Patients another primary malignancy within 3 year prior start study drug , exception adequately treat insitu carcinoma uterine cervix , skin cancer ( basal cell carcinoma , squamous cell carcinoma , nonmelanomatous skin cancer ) Patients receive last administration anticancer therapy include chemotherapy , immunotherapy , hormonal therapy monoclonal antibody ( exclude nitrosurea , mitomycinC , target therapy radiation ) less equal 4 week prior start study drug , recover side effect therapy Patients receive last administration nitrosurea mitomycinC less equal 6 week prior start study drug , recover side effect therapy Patients receive bevacizumab , sunitinib , sorafenib , pazopanib le equal 2 week prior start study drug , recover ( grade 1 ) side effect therapy . Patients radiotherapy less equal 4 week prior start study drug , less equal 2 week prior start study drug case localize radiotherapy ( e.g . analgesic purpose lytic lesion risk fracture ) , recover radiotherapy toxicity Patients therapeutic radiolabeled MIBG systemic radiolabeled therapy less equal 4 week prior start study drug , Patients undergone major surgery ( e.g . intrathoracic , intraabdominal intrapelvic ) , open biopsy significant traumatic injury less equal 4 week prior start study drug , patient minor procedure , percutaneous biopsy placement vascular access device 1 week prior start study drug , recover side effect procedure injury Patients follow concurrent severe and/or uncontrolled medical condition could compromise participation study ( i.e . impaired cardiac function clinically significant cardiac disease , etc ) . Pregnant breastfeed woman subject refuse use protocol require contraception Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>